Search results
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 12 hours agoPfizer disclosed on May 7 that a child participating in another...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks via Yahoo Finance· 16 hours agoPfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 9 hours agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Zacks via Yahoo Finance· 4 days agoPfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 18 hours agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
Pfizer, Flagship to focus on obesity drugs under $100M collaboration - Boston Business Journal
The Business Journals· 1 day agoAlmost a year after Cambridge’s Flagship Pioneering and Pfizer Inc. announced a partnership to...
Pfizer faces setback with gene therapy acquired from North Carolina firm - Triangle Business Journal
The Business Journals· 10 hours agoPfizer is facing a major clinical setback in a gene therapy program with ties to the Triangle. The...
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Market Watch· 16 hours agogained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a...
Pfizer gene therapy for Duchenne fails to meet goals of key trial
BioPharma Dive via Yahoo Finance· 1 day agoThe negative results from the Phase 3 study, called Ciffreo, come a little more than a month after ...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 1 day agoDespite a bevy of promising updates for its cancer treatments, Pfizer stock remains trapped below a...